FIT Biotech Oy (‘Company’) has received today a EUR 644,868 payment from its HIV collaborator, the European HIV Vaccine Alliance (EHVA). The payment was received as part of the contracted scheduled payments for manufacturing the Company’s investigational DNA-based HIV vaccine for a large multicenter Phase I/2 clinical trial planned to initiate later this year. EHVA is financed by the Horizon 2020 program of the European Commission.
FIT Biotech manufactures the investigational DNA-based HIV vaccine for EHVA in its own GMP production facility in Tampere, Finland, that is approved by the Finnish Medicines Agency (Fimea). This facility has the capacity to produce investigational drugs up to Phase 2 clinical trials, thus ensuring a rapid capability to introduce new DNA-based drug candidates to clinical trials.